Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2921PDF: 872HTML: 6538Untitled: 250Untitled: 203Untitled: 224Untitled: 231 -
-
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1304PDF: 781HTML: 327 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1213PDF: 775HTML: 1496Figure 1: 196Figure 2: 199 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3715PDF: 913HTML: 6728 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2627PDF: 819HTML: 5241 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1832PDF: 1188HTML: 258 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1801PDF: 839HTML: 183 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3448PDF: 1181HTML: 454 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3026PDF: 1609HTML: 240 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
4017PDF: 765HTML: 1858 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2160PDF: 1560HTML: 536 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
1039PDF: 1036Suppl. Files: 652HTML: 153 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7742PDF: 2455HTML: 1745Table 1.: 227Table 2.: 239Table 3.: 222Table 4.: 216 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
845PDF: 429HTML: 304 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2365PDF: 1673HTML: 305 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2683PDF: 763HTML: 2319 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1220PDF: 853HTML: 3368 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1460PDF: 1344HTML: 109 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1610PDF: 1059HTML: 263 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1548PDF: 1099HTML: 226 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2161PDF: 1337HTML: 3508 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1291PDF: 1036HTML: 235 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1100PDF: 536Suppl. Files: 132HTML: 283







